Advertisement
Advertisement
U.S. Markets open in 3 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Vyant Bio, Inc. (VYNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5650+0.0415 (+7.93%)
At close: 04:00PM EDT
0.5923 +0.03 (+4.83%)
After hours: 04:06PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5235
Open0.6000
Bid0.5002 x 1100
Ask0.6500 x 1800
Day's Range0.5626 - 0.6000
52 Week Range0.5000 - 3.2400
Volume19,225
Avg. Volume25,139
Market Cap16.379M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1500
Earnings DateNov 09, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • GlobeNewswire

    Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022

    -Invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines h

  • GlobeNewswire

    Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will be presenting at the H.C. Wainwright 24th A

  • GlobeNewswire

    Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

    Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance from the International Rett Syndrome FoundationContinued progress with efforts towards the divestiture of the vivoPharm businessProgress with licensing our iPSC technology to transition key product sales customers Financial Highlights $11.7 mi

Advertisement
Advertisement